PEGINTERFERON BETA-1A

Summary

Peginterferon Beta-1A (CHEMBL2108677) is an approved protein (ATC L03AB13); indicated across 4 conditions including neoplasm and multiple sclerosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L03AB13
• Indications: 4 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108677
Name	PEGINTERFERON BETA-1A
Type	Protein
Max phase	4
ATC	L03AB13

Also known as: BIIB-017, BIIB017, Biib017, Peginterferon beta, Peginterferon beta-1a, Plegridy, PEGINTERFERON BETA-1A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
multiple sclerosis	4	MONDO:0005301	MONDO:0005301
relapsing-remitting multiple sclerosis	3	MONDO:0005314	EFO:0003929
kidney failure	1	MONDO:0001106	HP:0000083

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE3	5
PHASE4	4
PHASE1	3
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02568111	PHASE4	WITHDRAWN	Brimonidine Tartrate for the Treatment of Injection Related Erythema
NCT02587065	PHASE4	COMPLETED	Plegridy Satisfaction Study in Participants
NCT03177083	PHASE4	COMPLETED	Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
NCT03424733	PHASE4	UNKNOWN	Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
NCT01332019	PHASE3	COMPLETED	Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
NCT01337427	PHASE3	WITHDRAWN	Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
NCT01939002	PHASE3	COMPLETED	Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
NCT03870763	PHASE3	TERMINATED	Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
NCT04552379	PHASE3	COMPLETED	The Containing Coronavirus Disease 19 (COVID-19) Trial
NCT01978652	PHASE1	COMPLETED	Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.
NCT02269930	PHASE1	COMPLETED	Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
NCT04183491	PHASE1	COMPLETED	Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
NCT05688436	Not specified	RECRUITING	A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
NCT01911767	Not specified	COMPLETED	Biogen Multiple Sclerosis Pregnancy Exposure Registry
NCT02230969	Not specified	COMPLETED	Plegridy Observational Program

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).